Literature DB >> 28161701

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

Krisztina Horváth1, Zsuzsanna Aschermann, Márton Kovács, Attila Makkos, Márk Harmat, József Janszky, Sámuel Komoly, Kázmér Karádi, Norbert Kovács.   

Abstract

BACKGROUND: Minimal clinically important difference (MCID) is the smallest change in an outcome, which a patient identifies as meaningful. Although the 2 most frequently applied Parkinson's disease (PD) "quality of life" questionnaires (the PDQ-39 and PDQ-8) provide encouragingly similar results, their MCID thresholds appear to be vastly different. Our aim was to calculate the MCID estimates for both PDQ-39 and PDQ-8 Summary Indices (PDQ-39-SI and PDQ-8-SI) by the utilization of both anchor- and distribution-based techniques.
METHODS: Nine hundred eighty-five paired investigations of 365 patients were included. Three different techniques were used simultaneously to calculate the MCID values.
RESULTS: First, we replicated the previously published results demonstrating how both PDQ-39-SI and PDQ-8-SI provide similar values and respond in a similar way to changes. Subsequently, we calculated the MCID thresholds. The most optimal estimates for MCID thresholds for PDQ-39-SI were -4.72 and +4.22 for detecting minimal clinically important improvement and worsening. For PDQ-8-SI, these estimates were -5.94 and +4.91 points for detecting minimal clinically important improvement and worsening respectively.
CONCLUSIONS: Our study is the first one that directly compared the MCID estimates for both PDQ-39-SI and PDQ-8-SI on a large pool of patients including all disease severity stages. These MICD estimates varied across PD severity.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Minimal clinically important change; Minimal clinically important difference; Parkinson’s disease; Patient reported outcomes; Receiver operating characteristic curve

Mesh:

Year:  2017        PMID: 28161701     DOI: 10.1159/000455863

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  30 in total

1.  Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.

Authors:  Dongni Johansson; Anders Ericsson; Anders Johansson; Alexander Medvedev; Dag Nyholm; Fredrik Ohlsson; Marina Senek; Jack Spira; Ilias Thomas; Jerker Westin; Filip Bergquist
Journal:  CNS Neurosci Ther       Date:  2018-01-25       Impact factor: 5.243

2.  GLP-1 receptor agonists for Parkinson's disease.

Authors:  Caroline A Mulvaney; Gonçalo S Duarte; Joel Handley; David Jw Evans; Suresh Menon; Richard Wyse; Hedley Ca Emsley
Journal:  Cochrane Database Syst Rev       Date:  2020-07-23

3.  Dance classes improve self-esteem and quality of life in persons with Parkinson's disease.

Authors:  Wya Feenstra; Jorik Nonnekes; Tahmina Rahimi; Heleen A Reinders-Messelink; Pieter U Dijkstra; Bas R Bloem
Journal:  J Neurol       Date:  2022-06-28       Impact factor: 6.682

4.  Profile of social self-management practices in daily life with Parkinson's disease is associated with symptom severity and health quality of life.

Authors:  Linda Tickle-Degnen; Michael T Stevenson; Sarah D Gunnery; Marie Saint-Hilaire; Cathi A Thomas; Linda Sprague Martinez; Barbara Habermann; Elena N Naumova
Journal:  Disabil Rehabil       Date:  2020-04-01       Impact factor: 3.033

Review 5.  Cost-Effectiveness of Deep Brain Stimulation With Movement Disorders: A Systematic Review.

Authors:  Tho Thi Hai Dang; David Rowell; Luke B Connelly
Journal:  Mov Disord Clin Pract       Date:  2019-05-17

Review 6.  The Evolution of Quality of Life After Subthalamic Stimulation for Parkinson's Disease: A Meta-Analysis.

Authors:  Charlotte Büttner; Marike Maack; Kathrin Janitzky; Karsten Witt
Journal:  Mov Disord Clin Pract       Date:  2019-08-16

7.  Effectiveness of a dance-physiotherapy combined intervention in Parkinson's disease: a randomized controlled pilot trial.

Authors:  Elisa Frisaldi; Piero Bottino; Margherita Fabbri; Marco Trucco; Alessandra De Ceglia; Nadia Esposito; Diletta Barbiani; Eleonora Maria Camerone; Federico Costa; Cristina Destefanis; Edoardo Milano; Giuseppe Massazza; Maurizio Zibetti; Leonardo Lopiano; Fabrizio Benedetti
Journal:  Neurol Sci       Date:  2021-03-20       Impact factor: 3.307

Review 8.  The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.

Authors:  Angelo Antonini; Per Odin; Rajesh Pahwa; Jason Aldred; Ali Alobaidi; Yash J Jalundhwala; Pavnit Kukreja; Lars Bergmann; Sushmitha Inguva; Yanjun Bao; K Ray Chaudhuri
Journal:  Adv Ther       Date:  2021-05-20       Impact factor: 3.845

9.  Prevalence and profile of nocturnal disturbances in Chinese patients with advanced-stage Parkinson's disease: a cross-sectional epidemiology study.

Authors:  Guiying He; Chun-Feng Liu; Qinyong Ye; Zhenguo Liu; Miao Jin; Huifang Shang; Ling Chen; Houzhen Tuo; Hong Jiang; Jifu Cai; Kalpesh Joshi; James Cooper; Lu Zi; Shengdi Chen
Journal:  BMC Neurol       Date:  2021-05-12       Impact factor: 2.474

10.  Enhancing Quality of Life in Indian Parkinson's Disease Patients with Improved Measurement of Psychological Domains: A Perspective.

Authors:  Ashima Nehra; Priya Sharma; Avneesh Narain; Shivani Sharma; Garima Joshi; Priyanka Bhat; Rajesh Kumar Singh; Roopa Rajan; Vinay Goyal; Achal Kumar Srivastava
Journal:  Ann Indian Acad Neurol       Date:  2021-04-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.